Skip to main content

Table 2 Cox regression analysis

From: Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

 

HR (95% CI)

Sex

 Male vs female

0.92 (0.58–1.46) p = 0.73

Age

 > 62 vs < 62

0.70 (0.44–1.12) p = 0.13

BRAF

 mut vs wt

1.06 (0.66–1.70) p = 0.81

LDH

 High vs normal

1.62 (0.86–3.04) p = 0.13

 Very high vs normal

4.64 (2.52–8.54) p < 0.0001

Brain metastasis

 Yes vs no

1.92 (1.18–3.11) p = 0.008

Previous lines of treatment

 2 vs 1

1.12 (0.62–2.02) p = 0.69

 ≥ 3 vs 1

1.38 (0.75–2.54) p = 0.30

Metastatic site

 Lung vs soft tissue

0.76 (0.30–1.87) p = 0.54

 Visceral vs soft tissue

1.85 (0.93–3.65) p = 0.08

Absolute lymphocyte count

0.87 (0.60–1.25) p = 0.45

Relative lymphocyte count (≥ 20 vs < 20)

0.96 (0.93–0.98) p = 0.001

Relative monocyte count

0.94 (0.82–1.06) p = 0.32

Relative eosinophil count (≥ 1.5 vs < 1.5)

0.75 (0.62–0.92) p = 0.006

Absolute neutrophil count (≥ 8 vs < 8)

1.11 (1.04–1.17) p = 0.001

Relative neutrophil count (≥ 70 vs < 70)

1.04 (1.01–1.06) p = 0.001

NLR

1.04 (1.02–1.06) p < 0.0001

dNLR

1.09 (1.04–1.14) p < 0.0001

Tot CD8+ cells

 ≥ 25.1 vs < 25.1

1.37 (0.86–2.18) p = 0.18

CD8+CD73+ cells (≥ 5.8 vs < 5.8)

1.55 (0.97–2.48) p = 0.07

CD8+PD-1+ cells (≥ 9.8 vs < 9.8)

1.86 (1.17–2.98) p = 0.009

CD8+PD-1+CD73+ cells (≥ 2.3 vs < 2.3)

2.25 (1.39–3.63) p = 0.001

  1. HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, NLR neutrophil-to-lymphocyte ratio, dNLR derived NLR